Literature DB >> 9989806

Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4.

S Jinno1, S C Hung, H Okayama.   

Abstract

In mammals Cdk4 (or Cdk6 in some cell types) is required for starting the cell cycle. Recently we showed that Cdk4 is regulated by tyrosine phosphorylation and dephosphorylation, and that this regulation is required for a DNA damage-induced G1 arrest. We report here that a generic anti-phosphotyrosine antibody can detect tyrosine-phosphorylated Cdk4 and that as revealed by immunoblot detection and kinase assay, this regulation is employed for DNA damage-responsive checkpoint control during cell cycle start from quiescence. In rat fibroblasts traversing G1 or arrested in G1 by deprivation of anchorage, Cdk4 does not undergo tyrosine phosphorylation. Tyrosine phosphorylation occurs only during cell's arrest in quiescence and dephosphorylation during their cell cycle start. Ultraviolet irradiation blocks dephosphorylation and concomitant activation of Cdk4, thereby preventing the start of cell cycling. Thus, unlike tyrosine phosphorylation of Cdc2, which controls phase transition in the regular cell cycle, tyrosine phosphorylation of Cdk4 is employed for controlling cell cycle start from quiescence in a rat fibroblast.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989806     DOI: 10.1038/sj.onc.1202347

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  CDC25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest.

Authors:  T Bertero; C Gastaldi; I Bourget-Ponzio; B Mari; G Meneguzzi; P Barbry; G Ponzio; R Rezzonico
Journal:  Cell Death Differ       Date:  2013-02-22       Impact factor: 15.828

2.  Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors".

Authors:  Laurence Bockstaele; Hugues Kooken; Frederick Libert; Sabine Paternot; Jacques E Dumont; Yvan de Launoit; Pierre P Roger; Katia Coulonval
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

3.  Oncogenic stimulation recruits cyclin-dependent kinase in the cell cycle start in rat fibroblast.

Authors:  S Jinno; S C Hung; H Yamamoto; J Lin; A Nagata; H Okayama
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

4.  Nucleolar GTP-binding Protein-1 (NGP-1) Promotes G1 to S Phase Transition by Activating Cyclin-dependent Kinase Inhibitor p21 Cip1/Waf1.

Authors:  Debduti Datta; Kumaraswamy Anbarasu; Suryaraja Rajabather; Rangasamy Sneha Priya; Pavitra Desai; Sundarasamy Mahalingam
Journal:  J Biol Chem       Date:  2015-07-09       Impact factor: 5.157

Review 5.  Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.

Authors:  Rebecca A Sager; Sarah J Backe; Elham Ahanin; Garrett Smith; Imad Nsouli; Mark R Woodford; Gennady Bratslavsky; Dimitra Bourboulia; Mehdi Mollapour
Journal:  Nat Rev Urol       Date:  2022-03-09       Impact factor: 16.430

6.  Activation and inhibition of cyclin-dependent kinase-2 by phosphorylation; a molecular dynamics study reveals the functional importance of the glycine-rich loop.

Authors:  Iveta Bártová; Michal Otyepka; Zdenek Kríz; Jaroslav Koca
Journal:  Protein Sci       Date:  2004-05-07       Impact factor: 6.725

7.  G(1)/S CDK is inhibited to restrain mitotic onset when DNA replication is blocked in fission yeast.

Authors:  Patrick Zarzov; Anabelle Decottignies; Giuseppe Baldacci; Paul Nurse
Journal:  EMBO J       Date:  2002-07-01       Impact factor: 11.598

8.  Regulation of CDK4.

Authors:  Laurence Bockstaele; Katia Coulonval; Hugues Kooken; Sabine Paternot; Pierre P Roger
Journal:  Cell Div       Date:  2006-11-08       Impact factor: 5.130

Review 9.  Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment.

Authors:  Oana-Maria Thoma; Markus F Neurath; Maximilian J Waldner
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.